In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pulse Biosciences (PLSE), with a price target of $16.00. The company’s shares closed last Monday at $11.89.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 3.8% and a 36.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
Pulse Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
See today’s analyst top recommended stocks >>
Based on Pulse Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.33 million. In comparison, last year the company had a GAAP net loss of $11.36 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pulse Biosciences, Inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary Nano-Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.